These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 20110029)

  • 1. Effects of imiglucerase treatment on traumatic fracture and bone and blood abnormalities in a patient with previously untreated type 1 gaucher disease.
    Boiret-Dupré N; Descamps S; Coudoré MA; Rapatel C; Kuentz M; Pereira S; Tournadre J; Berger J; Morell P; Berger MG
    Clin Ther; 2009 Dec; 31(12):2900-4. PubMed ID: 20110029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The female Gaucher patient: the impact of enzyme replacement therapy around key reproductive events (menstruation, pregnancy and menopause).
    Zimran A; Morris E; Mengel E; Kaplan P; Belmatoug N; Hughes DA; Malinova V; Heitner R; Sobreira E; Mrsić M; Granovsky-Grisaru S; Amato D; vom Dahl S
    Blood Cells Mol Dis; 2009; 43(3):264-88. PubMed ID: 19502088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease.
    Wenstrup RJ; Kacena KA; Kaplan P; Pastores GM; Prakash-Cheng A; Zimran A; Hangartner TN
    J Bone Miner Res; 2007 Jan; 22(1):119-26. PubMed ID: 17032149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A retrospective study on enzyme replacement therapy in patients with Gaucher disease].
    Duan YL; Zhang YH; Zang Y; Shi HP; Zhang WM; Hu YM
    Zhonghua Er Ke Za Zhi; 2006 Sep; 44(9):653-6. PubMed ID: 17217655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The International Collaborative Gaucher Group GRAF (Gaucher Risk Assessment for Fracture) score: a composite risk score for assessing adult fracture risk in imiglucerase-treated Gaucher disease type 1 patients.
    Deegan P; Khan A; Camelo JS; Batista JL; Weinreb N
    Orphanet J Rare Dis; 2021 Feb; 16(1):92. PubMed ID: 33602299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of imiglucerase supply constraint on the therapeutic management and course of disease in French patients with Gaucher disease type 1.
    Stirnemann J; Rose C; Serratrice C; Dalbies F; Lidove O; Masseau A; Pers YM; Baron C; Belmatoug N
    Orphanet J Rare Dis; 2015 May; 10():62. PubMed ID: 25968608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Spanish Gaucher disease patients after a 6-month imiglucerase shortage.
    Giraldo P; Irún P; Alfonso P; Dalmau J; Fernández-Galán MA; Figueredo A; Hernández-Rivas JM; Julia A; Luño E; Marín-Jimenez F; Martín-Nuñez G; Montserrat JL; de la Serna J; Vidaller A; Villalón L; Pocovi M
    Blood Cells Mol Dis; 2011 Jan; 46(1):115-8. PubMed ID: 20934891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Velaglucerase alfa for the management of type 1 Gaucher disease.
    Morris JL
    Clin Ther; 2012 Feb; 34(2):259-71. PubMed ID: 22264444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gaucher disease type 1 patients from the ICGG Gaucher Registry sustain initial clinical improvements during twenty years of imiglucerase treatment.
    Weinreb NJ; Camelo JS; Charrow J; McClain MR; Mistry P; Belmatoug N;
    Mol Genet Metab; 2021 Feb; 132(2):100-111. PubMed ID: 33485799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease.
    Ben Turkia H; Gonzalez DE; Barton NW; Zimran A; Kabra M; Lukina EA; Giraldo P; Kisinovsky I; Bavdekar A; Ben Dridi MF; Gupta N; Kishnani PS; Sureshkumar EK; Wang N; Crombez E; Bhirangi K; Mehta A
    Am J Hematol; 2013 Mar; 88(3):179-84. PubMed ID: 23400823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enzyme replacement therapy with imiglucerase in Taiwanese patients with type I Gaucher disease.
    Hsu CC; Chien YH; Lai MY; Hwu WL
    J Formos Med Assoc; 2002 Sep; 101(9):627-31. PubMed ID: 12645190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteopenia in Gaucher disease develops early in life: response to imiglucerase enzyme therapy in children, adolescents and adults.
    Mistry PK; Weinreb NJ; Kaplan P; Cole JA; Gwosdow AR; Hangartner T
    Blood Cells Mol Dis; 2011 Jan; 46(1):66-72. PubMed ID: 21112800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enzyme replacement therapy with imiglucerase in a Taiwanese child with type 1 Gaucher disease.
    Lin HY; Lin SP; Chuang CK; Wraith JE
    J Chin Med Assoc; 2006 May; 69(5):228-32. PubMed ID: 16835986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Own clinical experience with functional bracing for treatment of pseudarthrosis and delayed union of the tibia.
    Bara T; Sibiński M; Synder M
    Ortop Traumatol Rehabil; 2007; 9(3):259-63. PubMed ID: 17721423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a panel of highly sensitive, equivalent assays for detection of antibody responses to velaglucerase alfa or imiglucerase enzyme replacement therapy in patients with Gaucher disease.
    Séllos-Moura M; Barzegar S; Pan L; Shi P; Oommen S; Durant J; Ruiz JA
    J Immunol Methods; 2011 Oct; 373(1-2):45-53. PubMed ID: 21846471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined miglustat and enzyme replacement therapy in two patients with type 1 Gaucher disease: two case reports.
    Amato D; Patterson MA
    J Med Case Rep; 2018 Jan; 12(1):19. PubMed ID: 29373994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Velaglucerase alfa, a human recombinant glucocerebrosidase enzyme replacement therapy for type 1 Gaucher disease.
    Pastores GM
    Curr Opin Investig Drugs; 2010 Apr; 11(4):472-8. PubMed ID: 20336596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of switching from a reduced dose imiglucerase to velaglucerase in type 1 Gaucher disease: clinical and biochemical outcomes.
    van Dussen L; Cox TM; Hendriks EJ; Morris E; Akkerman EM; Maas M; Groener JE; Aerts JM; Deegan PB; Hollak CE
    Haematologica; 2012 Dec; 97(12):1850-4. PubMed ID: 22773601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The management of Gaucher disease in developing countries: a successful experience in Southern Brazil.
    Krug BC; Schwartz IV; Lopes de Oliveira F; Alegra T; Campos Martins NL; Todeschini LA; Picon PD
    Public Health Genomics; 2010; 13(1):27-33. PubMed ID: 19407439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of congenital pseudarthrosis of the tibia with recombinant human bone morphogenetic protein-7 (rhBMP-7). A report of five cases.
    Lee FY; Sinicropi SM; Lee FS; Vitale MG; Roye DP; Choi IH
    J Bone Joint Surg Am; 2006 Mar; 88(3):627-33. PubMed ID: 16510831
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.